Email this article Analysis of polymorphic variants of the survivin promoter and p53 transcription factor in patients with genital endometriosis, type 1 diabetes mellitus and their combination
- Authors: Andreeva N.Y.1, Ivaschenko T.E.1, Yarmolinskaya M.I.1,2, Misharina E.V.1, Shagina A.A.3, Sergeeva M.L.2
-
Affiliations:
- D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine
- North-Western State Medical University named after I.I. Mechnikov
- Medical Diagnostic Center (Genetic Medical Center)
- Issue: Vol 71, No 2 (2022)
- Pages: 17-28
- Section: Original Research
- URL: https://journals.eco-vector.com/jowd/article/view/89528
- DOI: https://doi.org/10.17816/JOWD89528
- ID: 89528
Cite item
Open Access
Access granted
Abstract
AIM: The aim of this study was to analyze the association between the SNP surviving, the p53 gene polymorphisms and the risk of developing genital endometriosis and type 1 diabetes mellitus.
MATERIALS AND METHODS: The frequency of allelic variants of the BIRC5 and TP53 genes was studied by PCR-RFLP analysis in 243 women, including 84 patients with genital endometriosis (stages I–IV), 85 patients with type 1 diabetes mellitus, 47 women with diabetes mellitus type 1 and endometriosis and 27 women of the control group represented by the population sample.
RESULTS: It was found that the frequency of the allele C polymorphic variant of rs9904341 in the BIRC5 gene was significantly higher in the group of patients with diseases compared to the population sample (p < 0.05). Significant differences for the C / C genotype in patients with genital endometriosis relative to the control group (p = 0.01) According to the odds ratio, the risk of developing genital endometriosis was 56 times higher for this genotype (ОR 56.31, CI 2.52–1258.7). Significant differences for the ins/ins genotype of TP53(p16) gene in patients with genital endometriosis relative to the control group (p = 0.005). According to the odds ratio, the risk of developing genital endometriosis was 94 times higher for this genotype (ОR 94.29, CI 3.88–2288.81). In addition, the frequency of the allele ins polymorphic variant of p16 in the TP53 gene was significantly higher in the group of patients with diseases compared to the control group (p < 0.05). The same results for the P allele of the rs1042522 polymorphism in the TP53 gene (p < 0.05). According to the odds ratio, the risk of developing genital endometriosis with diabetes mellitus type 1 was 3 times higher for G/A genotype of rs9930232 (p6) than for other genotypes (ОR 3.1, CI 2.52–1258.7)
CONCLUSIONS: The investigated factors can be considered as risk markers for the development of genital endometriosis and diabetes mellitus type one.
Full Text
About the authors
Nelly Y. Andreeva
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine
Email: nelly8352@yahoo.com
ORCID iD: 0000-0002-1928-1266
SPIN-code: 3355-2646
Russian Federation, Saint Petersburg
Tatiana E. Ivaschenko
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine
Email: tivashchenko2011@mail.ru
ORCID iD: 0000-0002-8549-6505
Scopus Author ID: 7004724202
PhD, Dr. Sci. (Biol.), Professor
Russian Federation, Saint PetersburgMaria I. Yarmolinskaya
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine; North-Western State Medical University named after I.I. Mechnikov
Email: m.yarmolinskaya@gmail.com
ORCID iD: 0000-0002-6551-4147
SPIN-code: 3686-3605
Scopus Author ID: 7801562649
ResearcherId: P-2183-2014
MD, Dr. Sci. (Med.), Professor, Professor of the Russian Academy of Sciences
Russian Federation, Saint Petersburg; Saint PetersburgElena V. Misharina
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine
Author for correspondence.
Email: mishellena@gmail.com
MD, Cand. Sci. (Med.)
Russian Federation, Saint PetersburgAnna A. Shagina
Medical Diagnostic Center (Genetic Medical Center)
Email: zero_18@list.ru
ORCID iD: 0000-0002-2276-6803
Russian Federation, Saint Petersburg
Maria L. Sergeeva
North-Western State Medical University named after I.I. Mechnikov
Email: masha9702@yandex.ru
ORCID iD: 0000-0002-3091-3834
Russian Federation, Saint Petersburg
References
- Yarmolinskaya MI, Aylamazyan EK. Genital'nyy endometrioz. Razlichnye grani problemy. Saint Petersburg: Eco-Vector; 2017. (In Russ.)
- Lin YH, Chen KJ, Peng YS, et al. Type 1 diabetes impairs female fertility even before it is diagnosed. Diabetes Res Clin Pract. 2018;143:151–158. doi: 10.1016/j.diabres.2018.07.010
- Mormile R, Vittori G. Type 1 diabetes in women with endometriosis: What is the risk of occurrence? J Pediatr Endocrinol Metab. 2013;26(9–10):1007–1008. doi: 10.1515/jpem-2013-0134
- Simmen RCM, Brown DM, Quick CM, et al. Co-morbidity of type 1 diabetes and endometriosis: bringing a new paradigm into focus. J Endocrinol. 2019;JOE-19-0248.R1. doi: 10.1530/JOE-19-0248
- Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17(10):2715–2724. DOI :10.1093/humrep/17.10.2715
- Shafrir AL, Palmor MC, Fourquet J, et al. Co-occurrence of immune-mediated conditions and endometriosis among adolescents and adult women. Am J Reprod Immunol. 2021;86(1):e13404. doi: 10.1111/aji.13404
- Wu X, Zhang Q, Wang X, et al. Survivin is required for beta-cell mass expansion in the pancreatic duct-ligated mouse model. PLoS One. 2012;7(8):e41976. doi: 10.1371/journal.pone.0041976
- Misharina EV, Yarmolinskaya MI, Ivashchenko TE, Andreyeva NY. The role of survivin in the pathogenesis of genital endometriosis, current application possibilities (literature review). Gynecology. 2020;22(6):11–15. (In Russ.). doi: 10.26442/20795696.2020.6.200486
- Fujino K, Ueda M, Takehara M, et al. Transcriptional expression of survivin and its splice variants in endometriosis. Mol Hum Reprod. 2006;12(6):383–388. doi: 10.1093/molehr/gal042
- Nabilsi NH, Broaddus RR, McCampbell AS, et al. Sex hormone regulation of survivin gene expression. J Endocrinol. 2010;207(2):237–243. doi: 10.1677/JOE-10-0128
- Nisenblat V, Bossuyt PM, Shaikh R, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016;2016(5):CD012179. doi: 10.1002/14651858.CD012179
- Wu X, Wang L, Schroer S, et al. Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice. Diabetologia. 2009;52(10):2130–2141. doi: 10.1007/s00125-009-1469-6
- Dohi T, Salz W, Costa M, et al. Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice. EMBO Rep. 2006;7(4):438–443. doi: 10.1038/sj.embor.7400640
- Moazeni-Roodi A, Ghavami S, Hashemi M. Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies. Int J Clin Oncol. 2019;24(4):335–349. doi: 10.1007/s10147-019-01408-y
- Zhu J, Xu RJ, Wu ZH, et al. Expression of survivin gene and its relationship with expression of p15, p16 proteins in laryngeal squamous cell carcinomas. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2004;39(6):356–359.
- Jang JW. Anti-tumor mechanisms and regulation of survivin by selective cyclooxygenase-2 inhibitor. Korean J Hepatol. 2008;14(3):305–308. doi: 10.3350/kjhep.2008.14.3.305
- Wagner M, Schmelz K, Dörken B, Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res. 2008;32(7):1054–1060. doi: 10.1016/j.leukres.2007.11.013
- Lamp M, Saare M, Kadastik Ü, et al. Survivin promoter polymorphisms and autoantibodies in endometriosis. J Reprod Immunol. 2012;96(1–2):95–100. doi: 10.1016/j.jri.2012.10.001
- Hillebrandt S, Streffer C, Demidchik EP, et al. Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutat Res. 1997;381(2):201–207. doi: 10.1016/s0027-5107(97)00169-3
- Malkinson AM, You M. The intronic structure of cancer-related genes regulates susceptibility to cancer. Mol Carcinog. 1994;10(2):61–65. doi: 10.1002/mc.2940100202
- Avigad S, Barel D, Blau O, et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene. 1997;14(13):1541–1545. doi: 10.1038/sj.onc.1200990
- Ivashchenko ТЕ, Golubeva ОВ, Shved NYu, et al. Role of polymorphism of p53 gene in pathogenesis of ovarian endometriosis. Journal of Obstetrics and Women’s Diseases. 2007;56(2):55–60. (In Russ.)
- Economopoulos KP, Sergentanis TN, Zagouri F, Zografos GC. Association between p53 Arg72Pro polymorphism and colorectal cancer risk: a meta-analysis. Onkologie. 2010;33(12):666–674. doi: 10.1159/000322210
- Ye F, Zhang J, Cheng Q, et al. p53 Codon 72 polymorphism is associated with occurrence of cervical carcinoma in the Chinese population. Cancer Lett. 2010;287(1):117–121. doi: 10.1016/j.canlet.2009.06.004
- Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25(11):1602–1611. doi: 10.1038/sj.onc.1209367
- Malinak LR, Buttram VC Jr, Elias S, Simpson JL. Heritage aspects of endometriosis. II. Clinical characteristics of familial endometriosis. Am J Obstet Gynecol. 1980;137(3):332–337.
- Li J, Chen Y, Mo Z, Li L. TP53 Arg72Pro polymorphism (rs1042522) and risk of endometriosis among Asian and Caucasian populations. Eur J Obstet Gynecol Reprod Biol. 2015;189:73–78. doi: 10.1016/j.ejogrb.2015.03.026
- Lao X, Chen Z, Qin A. p53 Arg72Pro polymorphism confers the susceptibility to endometriosis among Asian and Caucasian populations. Arch Gynecol Obstet. 2016;293(5):1023–1031. doi: 10.1007/s00404-015-3923-7
- Hussain R, Khaliq S, Raza SM, et al. Association of TP53 codon 72 polymorphism in women suffering from endometriosis from Lahore, Pakistan. J Pak Med Assoc. 2018;68(2):224–230.
- Manca Bitti ML, Saccucci P, Bottini E, Gloria-Bottini F. p53 codon 72 polymorphism and type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23(3):291–292. doi: 10.1515/jpem.2010.23.3.291
- Peller S, Kopilova Y, Slutzki S, et al. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 1995;14(12):983–990. doi: 10.1089/dna.1995.14.983
- Wang-Gohrke S, Weikel W, Risch H, et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer. 1999;81(1):179–183. doi: 10.1038/sj.bjc.6690669
- Pospelova TI, Voevoda MI,Voropaeva EN, et al. Value of constitutional polymorphisms gene р53 at patients with non-hodgkin’s lymphomas. Bulletin of Siberian Medicine. 2008;7(S3):56–63. (In Russ.)
Supplementary files
